Free Trial

Talphera (TLPH) Competitors

Talphera logo
$0.49 +0.01 (+1.21%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$0.48 -0.01 (-2.78%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TLPH vs. ITRM, SCYX, CLSD, RANI, EQ, AKTX, ALXO, ESLA, TPST, and CLNN

Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), Rani Therapeutics (RANI), Equillium (EQ), Akari Therapeutics (AKTX), ALX Oncology (ALXO), Estrella Immunopharma (ESLA), Tempest Therapeutics (TPST), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry.

Talphera vs. Its Competitors

Talphera (NASDAQ:TLPH) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 3.2% of Talphera shares are owned by company insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Talphera currently has a consensus target price of $5.00, suggesting a potential upside of 914.82%. Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,109.68%. Given Iterum Therapeutics' higher possible upside, analysts clearly believe Iterum Therapeutics is more favorable than Talphera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.50
Iterum Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Talphera has higher revenue and earnings than Iterum Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talphera$650K15.55-$13M-$0.40-1.23
Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.88

Talphera has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.85, meaning that its stock price is 185% more volatile than the S&P 500.

Iterum Therapeutics' return on equity of 0.00% beat Talphera's return on equity.

Company Net Margins Return on Equity Return on Assets
TalpheraN/A -152.38% -64.32%
Iterum Therapeutics N/A N/A -65.01%

In the previous week, Iterum Therapeutics had 1 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Iterum Therapeutics and 2 mentions for Talphera. Talphera's average media sentiment score of 0.20 beat Iterum Therapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Talphera
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Iterum Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Talphera beats Iterum Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLPH vs. The Competition

MetricTalpheraMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.99M$2.57B$5.76B$9.58B
Dividend YieldN/A1.67%4.41%4.10%
P/E Ratio-1.2322.6131.1026.05
Price / Sales15.55554.26433.22103.03
Price / CashN/A180.4637.7358.48
Price / Book1.545.939.536.61
Net Income-$13M$31.83M$3.26B$265.56M
7 Day Performance15.85%1.89%2.10%1.97%
1 Month Performance13.26%1.33%2.81%-0.36%
1 Year Performance-46.45%8.84%30.56%19.03%

Talphera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLPH
Talphera
2.8796 of 5 stars
$0.49
+1.2%
$5.00
+914.8%
-45.3%$9.99M$650K-1.2319Gap Down
ITRM
Iterum Therapeutics
1.8852 of 5 stars
$0.77
+8.4%
$9.00
+1,062.8%
-38.5%$33.72MN/A-0.8910
SCYX
SCYNEXIS
1.0268 of 5 stars
$0.86
-2.8%
N/A-51.4%$33.36M$3.75M-1.5360News Coverage
Analyst Revision
CLSD
Clearside Biomedical
1.8858 of 5 stars
$0.42
+5.2%
$4.20
+890.6%
-59.7%$33.29M$1.66M-1.1530
RANI
Rani Therapeutics
2.6886 of 5 stars
$0.53
+5.0%
$7.33
+1,296.8%
-79.7%$33.19M$1.03M-0.58110
EQ
Equillium
0.9699 of 5 stars
$0.94
+5.8%
$3.00
+220.2%
+102.2%$33.15M$41.10M-2.3840Gap Down
High Trading Volume
AKTX
Akari Therapeutics
2.4143 of 5 stars
$1.03
-2.4%
$5.00
+387.8%
-75.1%$32.98MN/A0.009
ALXO
ALX Oncology
3.0838 of 5 stars
$0.61
-0.1%
$3.30
+437.5%
-49.8%$32.79MN/A-0.2540Analyst Revision
ESLA
Estrella Immunopharma
2.3011 of 5 stars
$0.87
+0.6%
$16.00
+1,739.1%
-26.5%$31.47MN/A-3.35N/A
TPST
Tempest Therapeutics
1.2297 of 5 stars
$8.50
+6.1%
$30.00
+252.9%
-47.2%$31.28MN/A-0.4720
CLNN
Clene
3.2603 of 5 stars
$3.76
-1.5%
$40.00
+963.5%
+6.8%$31.10M$340K-0.93100Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TLPH) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners